Organogenesis Holdings Inc. provided earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net revenue of between $465 million and $490 million, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021. Net income in a range of approximately $26 million to $36 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.75 USD | +0.73% | +4.56% | -32.76% |
05-13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
05-10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.76% | 365M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022